Sanofi's Chattem launches OTC medicine Nasacort
Allergy 24HR Nasal Spray in US
Nasal Inhaler was taken off the market in July 2003 to comply with regulations from the FDA and Environmental Protection Agency.
Retailers are using on-shelf education, such as an in-store video on Nasacort
, to help consumers make decisions about which product to select.
Healthcare company Sanofi (EURONEXT:SAN)(NYSE:SNY), based in France, and its US consumer healthcare division Chattem, jointly reported on Tuesday the market availability of over-the-counter (OTC) Nasacort
Allergy 24HR Nasal Spray in the US.
The settlement halts a trial in Wilmington, Delaware, in which Sanofi accused Barr of infringing two patents for Nasacort
that it said produced about $300 million in annual U.
allergy nasal spray (30 sprays, from 3 nasacort
based Chattem, received approval of Nasacort
(triamcinolone acetonid) nasal spray in October 2013.
M2 PHARMA-October 15, 2013-Sanofi receives approval for Nasacort
Allergy 24HR from US Food and Drug Administration(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-October 15, 2013-Sanofi receives approval for Nasacort
Allergy 24HR from US Food and Drug Administration(C)2013 M2 COMMUNICATIONS http://www.
TABLE Intranasal steroids for treating allergic rhinitis Cost per Drug Usual adult dosages month * Beclomethasone dipropionate Beconase AQ 2 sprays/nostril qd $44 Vancenase AQ 2 sprays/nostril qd $40 Budesonide Rhinocort AQ 2 sprays/nostril bid $48 Flunisolide Nasarel 2 sprays/nostril bid $44 Nasalide 2 sprays/nostril bid $46 Fluticasone propionate Flonase 2 sprays/nostril qd $53 Mometasone furoate Nasonex 2 sprays/nostril qd $56 Triamcinolone acetonide Nasacort
AQ 2 sprays/nostril qd $56 bid, twice a day; qd, every day.
made its Nasacort
nasal allergy spray available without a prescription in 2014.